A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events
Latest Information Update: 13 Dec 2022
At a glance
- Drugs Insulin degludec (Primary) ; Insulin glargine
- Indications Cardiovascular disorders; Type 2 diabetes mellitus
- Focus Adverse reactions; Registrational
- Acronyms DEVOTE
- Sponsors Novo Nordisk
- 29 Jun 2021 Results (n=369) assessing association between cardiovascular autonomic neuropathy and risk of heart failure in patients with Type 2 Diabetes presented at the 81st Annual Scientific Sessions of the American Diabetes Association
- 25 Sep 2020 Results presented at the 56th Annual Meeting of the European Association for the Study of Diabetes
- 16 Jun 2020 Data from this trial used to assess derived time-in-range is associated with MACE in T2D presented at the 80th Annual Scientific Sessions of the American Diabetes Association